S&P 500
7,556.20
-0.01%
Dow Jones
52,600.00
-0.02%
Nasdaq 100
29,623.90
-0.03%
Russell 2000
2,965.77
-0.08%
FTSE 100
10,497.60
-0.13%
Nikkei 225
68,380.10
+0.26%

Investing

Pfizer Gets Okay for New Drug (PFE)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Pfizer Inc. (NYSE: PFE) has received approval from the US Food and Drug Administration to sell its kidney cancer drug, Inlyta, in the US. The drug is expected to generate about $140 million in revenues this year, and as much as $800 million annually by 2017.

Shares have not reacted, down about -0.7% currently, because the drug is the latest of seven treatments for kidney cancer.

Contact [email protected] for any questions or corrections.

Disclaimer: Energy Exploration Technologies, Inc. ("EnergyX") has engaged 24/7 Wall St to publish this communication in connection with EnergyX's ongoing Regulation A offering. 24/7 Wall St has been paid in cash and may receive additional compensation. 24/7 Wall St and/or its affiliates do not currently hold securities of EnergyX.

This compensation and any current or future ownership interest could create a conflict of interest. Please consider this disclosure alongside EnergyX's offering materials. EnergyX's Regulation A offering has been qualified by the SEC. Offers and sales may be made only by means of the qualified offering circular. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at invest.energyx.com/.

Comparisons to other companies are for informational purposes only and should not imply similar results. Past performance is not indicative of future results. Market shortfall are forward‑looking estimates and are subject to substantial uncertainty. Investments in private placements, and start-up investments in particular, are long-term, illiquid, speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Douglas A. McIntyre |

Pre-Market Stock News (DEC 4, 2006)

(AGR) Agere being acquired by LSI for 2.16 shares.(AH) Armor Holdings won a $649M truck order from Army.(ATI) Allegheny Tech…

Douglas A. McIntyre |

Onyx Pharma Tumbles As Skin Cancer Drug Fails Phase III

From BioHealth Investor Shares of Onyx Pharmaceuticals (ONXX) dropped more than 30% on Monday after the company announced at a…

Jon C. Ogg |

Lessons of Buying Growth Companies Doubling Their Revenues

ThinkstockAmgen Inc. (NASDAQ: AMGN) wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized…

What Americans Die From, What They Search For, and What the Media Covers Are Completely Different
Hristina Byrnes |

What Americans Die From, What They Search For, and What the Media Covers Are Completely Different

Heart disease is by far the leading cause of mortality in the United States, but it’s not the one that…

Jon C. Ogg |

JMP Securities Very Positive on Five Key Biotech Stocks (AMGN, BIIB, AFFY, ALNY, CELG, ONXX, PCYC, PFE, LLY, MRK, BMY)

ThinkstockInvesting in biotech or biopharmaceutical stocks can prove to be a very daunting task. Many of the stocks have limited…

The World’s Most Often Prescribed Drug Might Be Killing Us
Hristina Byrnes |

The World’s Most Often Prescribed Drug Might Be Killing Us

Proton pump inhibitors (PPIs) — a widely prescribed group of medications that combat heartburn, GERD (gastroesophageal reflux disease), and ulcers…

Douglas A. McIntyre |

US Stock Market Wrap (DEC 4, 2006)

DJIA    12,283.85; Up 89.72  (0.74%)NASDAQ    2,448.39; Up 35.18 (1.46%)S&P500    1,409.12; Up 12.41 (0.89%)10YR-Bond    4.433%     Up…

Douglas A. McIntyre |

Amgen (AMGN) And Johnson & Johnson (JNJ): When The Patients Die

Two of the best-selling drugs in the US are Procrit from Johnson & Johnson (NYSE: JNJ) and Aranesp from Amgen…

Douglas A. McIntyre |

Genentech Mixes Top-Line & Bottom-Line Numbers (DNA)

Genentech, Inc. (NYSE: DNA) today posted earnings of $0.81 per share and $3.408 billion in revenue. That’s below First Call…

Top Gaining Stocks

CrowdStrike
CRWD • Vol: 11,983,479
Goldman Sachs
GS • Vol: 3,787,930
Dell Technologies
DELL • Vol: 7,221,916
Palo Alto Networks
PANW • Vol: 5,890,623
Monolithic Power Systems
MPWR • Vol: 777,496

Top Losing Stocks

IBM
IBM • Vol: 67,221,239
Coterra Energy
CTRA • Vol: 73,319,495
Biogen
BIIB • Vol: 3,821,790
HCA Healthcare
HCA • Vol: 4,227,565
Intuitive Surgical
ISRG • Vol: 5,651,099